Navlimetostat + mFOLFIRINOX for Pancreatic Cancer

(M-POP Trial)

This trial tests a new combination of treatments for individuals with localized pancreatic cancer. The goal is to determine if navlimetostat is safe and effective when combined with mFOLFIRINOX (a chemotherapy regimen) before and after surgery. Participants should have pancreatic cancer that hasn't spread, and their tumors must exhibit a specific genetic change called MTAP deletion. This trial could provide a new option for those newly diagnosed and not yet treated. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, giving participants the opportunity to be among the first to receive this new drug combination.

Research shows that navlimetostat is generally well-tolerated by patients. In earlier studies involving individuals with advanced pancreatic cancer, navlimetostat demonstrated lasting tumor-fighting effects with few serious side effects. Most patients managed the treatment well, experiencing a low occurrence of blood-related side effects.

Navlimetostat is unique because it targets a specific enzyme involved in the progression of pancreatic cancer, potentially offering a more precise approach than current treatments. Most treatments for pancreatic cancer, like the standard mFOLFIRINOX chemotherapy regimen, attack rapidly dividing cells in general, which can affect both cancerous and healthy cells. Navlimetostat, on the other hand, is designed to interfere directly with cancer cell growth pathways, which might reduce side effects and improve effectiveness. Researchers are excited about this treatment because it could provide a more targeted and potentially less toxic option for patients.

Research has shown that navlimetostat, under study in this trial, may help treat pancreatic cancer. In one study, patients lived for an average of 20 months, longer than with other treatments. This suggests that, on average, patients experienced extended survival. The treatment also delayed cancer progression for a longer period. Although more information is needed, these early results suggest navlimetostat could be a promising option for pancreatic cancer with MTAP deletion.⁶⁷⁸⁹¹⁰